82.6 %
SAFETY
AREXVY has an acceptable safety profile . 2 , 3
Very common adverse events ( ≥10 %) are headache , myalgia , arthralgia , injection site pain and fatigue . Common adverse events ( ≥1 %) are injection site erythema , injection site swelling , fever , chills and rhinorrhoea ( not a complete list ; see full PI ). 1
67.2 %
SCAN QR CODE to see full AREXVY Product Information
Please review Product Information before prescribing . Product Information can be accessed at www . gsk . com . au / arexvy
▼This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
PBS Information : AREXVY is not listed on the PBS or the National Immunisation Program ( NIP ).
Dosing and administration : AREXVY is administered as a single , reconstituted dose of 0.5 mL by intramuscular injection . The need for revaccination has not been established . 1